Immunodeficiency: Gene therapy for primary immune deficiency.

Area of Science:

• Immunology
• Genetics
• Biotechnology

Background:

• Current gene therapy for inborn errors of immunity (IEI) primarily uses gene addition via viral vectors.
• This approach has shown success in conditions like severe combined immune deficiency, Wiskott-Aldrich syndrome, and chronic granulomatous disease.
• Hematopoietic stem cell transplantation remains the preferred treatment due to gene therapy limitations.

Purpose of the Study:

• To review the current state and future potential of gene therapy for IEI.
• To highlight advancements in gene therapy that may overcome existing limitations.
• To discuss the comparative advantages of improved gene therapy over hematopoietic stem cell transplantation.

Main Methods:

• Review of current gene therapy strategies for IEI.
• Discussion of next-generation lentiviral vectors for enhanced viral delivery.
• Exploration of CRISPR-Cas9 gene editing technology for IEI treatment.

Main Results:

• Gene addition therapy has demonstrated success in specific IEI.
• Next-generation vectors and CRISPR-Cas9 offer improved efficacy and safety profiles.
• These advancements reduce transplantation-related complications, enhancing gene therapy's viability.

Conclusions:

• Gene therapy for IEI is rapidly evolving with technological advancements.
• Improved gene therapy approaches are expected to surpass hematopoietic stem cell transplantation in efficacy and safety.
• The scope of gene therapy for IEI is anticipated to broaden, benefiting more patients.